Clinical Study
Oral HIV-Associated Kaposi Sarcoma: A Clinical Study from the Ga-Rankuwa Area, South Africa
Table 3
CD4+ T-cell counts (cells/mm3) of the participants.
| | CD4+ T-cell counts of the patients | Males | Females | Average |
| | At the time of oral HIV-KS diagnosis (33 patients) | 141 (14) | 85 (19) | 107 (33) | | Standard deviation | 117.40 | 77.99 | 106.99 | | Who were simultaneously diagnosed with HIV and oral KS (14 patients) | 163 (7) | 97 (7) | 130 (14) | | Standard deviation | 155.64 | 85.95 | 125.63 | | Who were diagnosed with HIV infection before developing oral HIV-KS, at the time of HIV diagnosis (14 patients) | 210 (6) | 129 (8) | 164 (14) | | Standard deviation | 167.27 | 160.21 | 162.14 | | Who were diagnosed with HIV infection before developing oral HIV-KS, at the time of oral HIV-KS diagnosis (19 patients) | 119 (7) | 74 (12) | 90 (19) | | Standard deviation | 112.92 | 75.55 | 90.75 | | Receiving for some time HAART, at HIV-KS diagnosis (7 patients) | 160 (1) | 78 (6) | 90 (7) | | Standard deviation | 0 | 71.49 | 72.19 | | Who were HAART-naïve at oral HIV-KS diagnosis (26 patients) | 140 (13) | 87 (13) | 114 (26) | | Standard deviation | 137.98 | 83.75 | 114.97 | | Who had facial lymphoedema during their course of oral HIV-KS (8 patients) | 24 (4) | 31 (4) | 28 (8) | | Standard deviation | 14.66 | 15.75 | 14.61 | | Who did not have lymphoedema during the course of oral HIV-KS (25 patients) | 188 (10) | 96 (15) | 133 (25) | | Standard deviation | 129.50 | 82.60 | 111.33 |
|
|
